Moreover, their selective accumulation within the tumor site may suggest that selective depletion of CCR4+ or CCR8+ Tregs may enhance anti-cancer immunity while having a very limited effect on Tregs in the periphery. The gene discussed is CCR4; the disease is neoplasm.